Abstract:It has been revealed by our previous proteomic study that the expression profile is different between well-differentiated and poorly differentiated hepatocellular carcinoma (HCC). Among those differently expressed proteins, peroxiredoxin2 (PRDX2) was our protein of interest. The present study aimed to further investigate the value of PRDX2 as a prognostic factor in HCC. Tissue microarrays were used to investigate the expression difference between HCC tissues and their adjacent normal liver tissues. The expression of PRDX2 at both mRNA and protein levels was examined by q-RT-PCR, western blotting and immunohistochemical assessment in HCC tissues and cell line HCCLM3. Silencing of PRDX2 in HCCLM3 was achieved usingpGMLV-SC1 lentiviral vectors. Cell Counting Kit-8 (CCK-8) and Transwell migration assays were used to assess cell proliferation and migration, respectively. Categorical variables were assessed using the Chi-square test, and ordinal variables were examined using the Mann-Whitney U test. The difference of continuous variables between groups were compared with t-tests. The Kaplan-Meier method was used to calculate the overall survival (OS) and disease-free survival (DFS) of patients, and the log-rank test was used to analyze the differences between groups. The results revealed that the expression of PRDX2 was decreased at both the mRNA and protein levels in an HCC cell line compared to that of a normal human liver cell line. PRDX2 protein expression levels were significantly downregulated in HCC tissues and were positively linked to overall survival (OS) and disease-free survival (DFS) of HCC patients. Patients with high PRDX2 expression levels had longer OS and DFS times than those with lower PRDX2 expression. Silencing of PRDX2 in the HCC cell line HCCLM3 promoted cancer cell proliferation and migration. Our findings indicated that PRDX2 may play an important role in HCC development; PRDX2 may serve as a useful prognostic factor and a therapeutic target.

MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer

Mir-383 Is Downregulated In Medulloblastoma And Targets Peroxiredoxin 3 (Prdx3)

MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.

MicroRNA-383 Promotes Reactive Oxygen Species-Induced Autophagy Via Downregulating Peroxiredoxin 3 in Human Glioma U87 Cells.

Silencing PRDX3 Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells

MicroRNA-107 Inhibits Proliferation of Prostate Cancer Cells by Targeting Cyclin E1.

Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression

Downregulated NOX4 underlies a novel inhibitory role of microRNA‐137 in prostate cancer

MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.

Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells.

Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.

MicroRNA‐487a‐3p Functions As a New Tumor Suppressor in Prostate Cancer by Targeting CCND1

Detection and Identification of Peroxiredoxin 3 As a Biomarker in Hepatocellular Carcinoma by a Proteomic Approach.

Mir199b Suppresses Expression Of Hypoxia-Inducible Factor 1 Alpha (Hif-1 Alpha) In Prostate Cancer Cells

miR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer

Downregulation of Mir-199A-5p Promotes Prostate Adeno-Carcinoma Progression Through Loss of Its Inhibition of HIF-1α.

Exosome-derived miR-23a-5p inhibits HCC proliferation and angiogenesis by regulating PRDX2 expression MiR-23a-5p/PRDX2 axis in HCC progression

Expression Profile of MicroRNAs in Prostate Carcinoma and Role of Mir-96 in Regulation of Oxidative Stress

MicroRNA-494-3p Targets CXCR4 to Suppress the Proliferation, Invasion, and Migration of Prostate Cancer

MicroRNA-340 Inhibits Prostate Cancer Cell Proliferation and Metastasis by Targeting the MDM2-p53 Pathway.

[Expression of Peroxiredoxin III in Cervical Lesions].